Phase I/II clinical trial of a helper peptide vaccine plus PD-1 blockade in PD-1 antibody-naïve and PD-1 antibody-experienced patients with melanoma (MEL64).
Quick Facts
What This Study Found
Key Numbers
How They Did This
Why This Research Matters
What This Study Doesn't Tell Us
Trust & Context
- Original Title:
- Phase I/II clinical trial of a helper peptide vaccine plus PD-1 blockade in PD-1 antibody-naïve and PD-1 antibody-experienced patients with melanoma (MEL64).
- Published In:
- Journal for immunotherapy of cancer, 10(9) (2022)
- Authors:
- Vavolizza, Rick Daniel, Petroni, Gina R, Mauldin, Ileana S, Chianese-Bullock, Kimberly A, Olson, Walter C, Smith, Kelly T, Dengel, Lynn T, Haden, Kathleen, Grosh, William W, Kaur, Varinder, Varhegyi, Nikole, Gaughan, Elizabeth M, Slingluff, Craig L
- Database ID:
- RPEP-06562
Evidence Hierarchy
Read More on RethinkPeptides
Related articles coming soon.
Cite This Study
https://rethinkpeptides.com/research/RPEP-06562APA
Vavolizza, Rick Daniel; Petroni, Gina R; Mauldin, Ileana S; Chianese-Bullock, Kimberly A; Olson, Walter C; Smith, Kelly T; Dengel, Lynn T; Haden, Kathleen; Grosh, William W; Kaur, Varinder; Varhegyi, Nikole; Gaughan, Elizabeth M; Slingluff, Craig L. (2022). Phase I/II clinical trial of a helper peptide vaccine plus PD-1 blockade in PD-1 antibody-naïve and PD-1 antibody-experienced patients with melanoma (MEL64).. Journal for immunotherapy of cancer, 10(9). https://doi.org/10.1136/jitc-2022-005424
MLA
Vavolizza, Rick Daniel, et al. "Phase I/II clinical trial of a helper peptide vaccine plus PD-1 blockade in PD-1 antibody-naïve and PD-1 antibody-experienced patients with melanoma (MEL64).." Journal for immunotherapy of cancer, 2022. https://doi.org/10.1136/jitc-2022-005424
RethinkPeptides
RethinkPeptides Research Database. "Phase I/II clinical trial of a helper peptide vaccine plus P..." RPEP-06562. Retrieved from https://rethinkpeptides.com/research/vavolizza-2022-phase-iii-clinical-trial
Access the Original Study
Study data sourced from PubMed, a service of the U.S. National Library of Medicine, National Institutes of Health.
This study breakdown was produced by the RethinkPeptides research team. We analyze and report published research findings without making health recommendations. All interpretations are based solely on the published abstract and study data.